Aug. 19 at 6:38 AM
$CMPS 430M in cash. 50Mdebt.
Q2 losses increased 22% to -52.4M.
G&A costs exploding. With full launch year to massively burn cash 💯
433M doesn't fully fund a standalone commercial build.
Standing up a specialty sales force, payer/reimbursement infrastructure, medical affairs, manufacturing scale-up, and DEA-rescheduling-dependent distribution for a drug targeting a market with roughly 4 million TRD patients in the U.S. is a multi-year, multi-hundred-million-to-billion-dollar undertaking — that's before you get into any post-launch marketing spend needed to actually convert the ~90% "willing to prescribe" survey response into real uptake.
